Covid-19. COVID-19 disease
Conditions
Interventions
Intervention 1: Intervention group: In addition to the standard treatment regimen for COVID-19, the crocetin capsule 22.5 mg (7.5 mg, three times a day) will be given for 2 weeks. Intervention 2: Cont
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients with COVID-19 symptoms Indication of home quarantine and outpatient medication
Exclusion criteria
Exclusion criteria: Patients over 65 years of age Patients connected to a catheter or under chemotherapy Patients taking cytotoxic drugs or corticosteroids Child patients Pregnant and lactating patients Diabetic patients Patients with severe renal insufficiency as well as liver failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time interval until clinical symptoms improve. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: time of recovery. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fever. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: Thermometer.;Lymphopenia. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: Cell counter device.;CRP. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: CRP kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHossein Hosseinzadeh
Mashhad University of Medical Sciences
Outcome results
None listed